421 research outputs found

    Symmetries of Quadrupole-Collective Vibrational Motion in Transitional Even-Even 124−134Xenon Nuclei

    Get PDF
    Projectile-Coulomb excitation of Xe isotopes has been performed at ANL using the Gammasphere array for the detection of γ-rays. The one-quadrupole phonon 2+ 1,ms mixed-symmetry state (MSS) has been traced in the stable N=80 isotones down to 134Xe. First, the data on absolute E2 andM1 transition rates quantify the amount of F-spin symmetry in these nuclei and provide a new local measure for the pn-QQ interaction. Second, the evolution of the 2+ 1,ms state has been studied along the sequence of stable even-even 124−134Xe isotopes that are considered to form a shape transition path from vibrational nuclei with vibrational U(5) symmetry near N=82 to γ-softly deformed shapes with almost O(6) symmetry. Third, our data on more than 50 absolute E2 transition rates between off-yrast low-spin states of 124,126Xe enable us to quantitatively test O(6) symmetry in these nuclei. As a result we find that O(6) symmetry is more strongly broken in the A=130 mass region than previously thought. The data will be discussed

    Autonomy and forage grasses in goat farming of western France First results of a sociological survey

    Get PDF
    International audienceOur communication is based on the results of a multidisciplinary research (PSDR FLECHE-Fromages et Laits issus d'Élevages de Chèvres conduites avec de l'Herbe-2016-2020) which aims to study the potential of grass valorization in goat systems, with the dual objective of strengthening the economic resilience of farms and the social image of the dairy goat sector of Western France. The latter currently represent almost half of the national goat population and 58% of the milk supplied in France. The sociological aspect of the research concerns the representations, value systems, interests and constraint systems (technical, economic, etc.) that guide the practices of all the actors in the sector: farmers, upstream and downstream actors. The objective of this approach is to analyse, at all levels of the value chain, the incentives and obstacles to a possible transition to more grassy feeding systems. Based on 76 semi-directive interviews, this paper presents the first results of this survey by showing how contextual elements (socio-economic, professional, etc.) impact farmers' choices of practices. While, in principle, the whole goat sector seems to be converging towards an agro-ecological transition that ensures its sustainability, in practice, each of its actors is confronted with a system of constraints that limit actual developments. The articulation of these obstacles seems to lead to a kind of inertia, which prevents the adoption of practices that are nevertheless perceived as recommendable by most actors. Autonomie et fourrages herbagers dans les élevages caprins de l'Ouest de la France. Premiers résultats d'une enquête sociologique. Résumé. Notre communication s'inscrit dans le cadre d'une recherche pluridisciplinaire (Programme PSDR-FLECHE-Fromages et Laits issus d'Élevages de Chèvres conduites avec de l'Herbe-2016-2020) qui vise à étudier le potentiel de valorisation de l'herbe dans les systèmes caprins, dans le double objectif de renforcer la résilience économique des exploitations et l'image sociale des filières caprines laitières de l'Ouest de la France. Ces dernières représentent actuellement près de la moitié de l'effectif national de chèvres et 58% du lait livré en France. Le volet sociologique de la recherche porte sur les représentations, les systèmes de valeurs, les intérêts et les systèmes de contraintes (techniques, économiques, etc.) qui orientent les pratiques de l'ensemble des acteurs de la filière : éleveurs, acteurs de l'amont et de l'aval. L'objectif de cette démarche est d'analyser, à tous les niveaux de la filière, les incitations et les freins à une éventuelle transition vers des systèmes alimentaires plus herbagers. A partir de 76 entretiens semi-directifs, ce papier présente les premiers résultats de cette enquête en montrant, notamment, comment les éléments contextuels (socio-économiques, professionnels, etc.) impactent les choix des pratiques des exploitants agricoles. Si, en principe, l'ensemble de la filière caprine semble converger vers une transition agroécologique qui en assure la durabilité, dans la pratique, chacun de ses acteurs est confronté à un univers de contraintes qui limitent les évolutions effectives. L'articulation des freins relevant des différents maillons de la filière, semble ainsi déboucher sur une sorte d'inertie, qui empêche l'adoption de pratiques pourtant perçues comme souhaitables par la plupart des acteurs. Mots-clés. Autonomie-fourrages herbagers-caprins-sociologie

    Evolution of the one-phonon 2(1,ms)(+) mixed-symmetry state in N=80 isotones as a local measure for the proton-neutron quadrupole interaction

    Get PDF
    An inverse kinematics Coulomb excitation experiment was performed to obtain absolute E2 and M1 transition strengths in 134Xe. The measured transition strengths indicate that the 23+ state of 134Xe is the dominant fragment of the one-phonon 21, ms+ mixed-symmetry state. Comparing the energy of the 21, ms+ mixed-symmetry state in 134Xe to that of the 21, ms+ levels in the N = 80 isotonic chain indicates that the separation in energy between the fully-symmetric 21+ state and the 21, ms+ level increases as a function of the number of proton pairs outside the Z = 50 shell closure. This behavior can be understood as resulting from the mixing of the basic components of a two-fluid quantum system. A phenomenological fit based on this concept was performed. It provides the first experimental estimate of the strength of the proton-neutron quadrupole interaction derived from nuclear collective states with symmetric and antisymmetric nature

    Diagnosis and management of anaemia and iron deficiency in patients with haematological malignancies or solid tumours in France in 2009-2010: the AnemOnHe study

    Get PDF
    OBJECTIVE: To describe the management of anaemia in 2009-2010 in France in patients with haematological malignancies (HM) or solid tumours (ST). METHODS: Retrospective observational study in 57 centres, enrolling adult patients with HM or ST treated for an episode of anaemia (duration of the episode >/= 3 months occurring in the last 12 months). RESULTS: 220 patients with ST (breast, 18%; lung, 18%) and 56 with HM (lymphoma, 60%) were included (median age, 68 years; female, 53%). Mean haemoglobin level at anaemia diagnosis was 9.3 +/- 1.4 g/dL (<8 g/dL for 16%) and 9.8 +/- 1.1g/dL (<8 g/dL for 6%) in HM and ST patients, respectively. At least one parameter of iron deficiency (ferritin, transferrin saturation) was assessed in 26% of HM and 19% of ST patients. Treatment of anaemia included erythropoiesis-stimulating agents (ESA) for 98% of HM and 89% of ST patients. Iron was prescribed to 14% (oral, 12%; intravenous, 2%) of HM patients and to 42% (oral, 17%; intravenous, 25%) of ST patients. The rates of blood transfusions were high: 70% in HM and 46% in ST patients; transfusions alone or administrated with ESA were more frequent in patients with Hb <8 g/dL. CONCLUSION: Although recent guidelines recommend evaluating iron deficiency and correcting anaemia by using intravenous iron, our study in cancer patients evidenced that ESA and blood transfusions are still frequently used as the treatment of anaemia in cancer patients. Iron deficiency is insufficiently assessed (only one patient among five) and as a consequence iron deficiency is most likely insufficiently treated

    Stellar and thermal neutron capture cross section of ⁹Be

    Get PDF
    The neutron capture cross section of ⁹Be for stellar energies was measured via the activation technique using the Karlsruhe Van de Graaff accelerator in combination with accelerator mass spectrometry at the Vienna Environmental Research Accelerator. To characterize the energy region of interest for astrophysical applications, activations were performed in a quasistellar neutron spectrum of kT = 25 keV and for a spectrum at En = 473 ± 53 keV. Despite the very small cross section, the method used provided the required sensitivity for obtaining fairly accurate results of 10.4 ± 0.6 and 8.4 ± 1.0 μb, respectively. With these data it was possible to constrain the cross section shape up to the first resonances at 622 and 812 keV, thus allowing for the determination of Maxwellian-averaged cross sections at thermal energies between kT = 5 and 100 keV. In addition, we report a new experimental cross section value at thermal energy of σth = 8.31 ± 0.52 mb.This work was partly funded by the Austrian Science Fund (FWF), Projects No. P20434 and No. I428, and by the Australian Research Council, Projects No. DP140100136 and No. DP180100496

    Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from Study 10 and ARIEL2

    Get PDF
    Objective: An integrated analysis was undertaken to characterize the antitumor activity and safety profile of the oral poly(ADP-ribose) polymerase inhibitor rucaparib in patients with relapsed high-grade ovarian carcinoma (HGOC). Methods: Eligible patients from Study 10 (NCT01482715) and ARIEL2 (NCT01891344) who received a starting dose of oral rucaparib 600 mg twice daily (BID) with or without food were included in these analyses. The integrated efficacy population included patients with HGOC and a deleterious germline or somatic BRCA1 or BRCA2 (BRCA1/2) mutation who received at least two prior chemotherapies and were sensitive, resistant, or refractory to platinum-based chemotherapy. The primary endpoint was investigator-assessed confirmed objective response rate (ORR). Secondary endpoints included duration of response (DOR) and progression-free survival (PFS). The integrated safety population included patients with HGOC who received at least one dose of rucaparib 600 mg BID, irrespective of BRCA1/2 mutation status and prior treatments. Results: In the efficacy population (n = 106), ORR was 53.8% (95% confidence interval [CI], 43.8–63.5); 8.5% and 45.3% of patients achieved complete and partial responses, respectively. Median DOR was 9.2 months (95% CI, 6.6–11.6). In the safety population (n = 377), the most frequent treatment-emergent adverse events (AEs) were nausea, asthenia/fatigue, vomiting, and anemia/hemoglobin decreased. The most common grade ≥ 3 treatment-emergent AE was anemia/hemoglobin decreased. Treatment-emergent AEs led to treatment interruption, dose reduction, and treatment discontinuation in 58.6%, 45.9%, and 9.8% of patients, respectively. No treatment-related deaths occurred. Conclusions: Rucaparib has antitumor activity in advanced BRCA1/2-mutated HGOC and a manageable safety profile

    A phase I/II study of 4 monthly courses of high-dose cyclophosphamide and thiotepa for metastatic breast cancer patients

    Get PDF
    This pilot phase I/II study intended to determine the maximum tolerated dose of cyclophosphamide and thiotepa administered on four consecutive courses with peripheral blood progenitor cell and granulocyte-colony stimulating factor support, as first-line therapy for hormone-refractory metastatic breast cancer patients. Twenty-eight patients were entered in the study. After two courses of epirubicin (120 mg m−2) and cyclophosphamide (2 g m−2) followed by granulocyte-colony stimulating factor injection and leukaphereses, patients received four cycles of cyclophosphamide and thiotepa. Each cycle was followed by peripheral blood progenitor cell and granulocyte-colony stimulating factor supports, then repeated every 28 to 35 days. Six escalating dose levels of cyclophosphamide and thiotepa were planned, beginning at cyclophosphamide 1.5 g m−2 and thiotepa 200 mg m−2. At least three patients were enrolled for each dose level. Eighteen patients completed the study. The maximum tolerated dose was 3000 mg m−2 cyclophosphamide and 400 mg m−2 thiotepa per course. Haematological toxicity was manageable on an outpatient basis and did not increase significantly with dose escalation. Dose-limiting toxicity was chemotherapy-induced immuno-suppression, which resulted in one toxic death and two life-threatening infections. Median times to treatment failure and survival were 11 and 26 months, respectively. Three patients were alive, free of disease 30 months after completion of the study. Such therapy allows for high-dose intensity and high cumulative doses on a short period of time with manageable toxicity

    Anti-angiogenic therapies for the treatment of angiosarcoma: a clinical update

    Get PDF
    Summary: Angiosarcomas are rare aggressive endothelial tumours, and are associated with a poor prognosis. Due to their vascular nature, there is great interest in their response to anti-angiogenic agents. A number of small prospective studies have reported angiosarcoma response to vascular-targeted agents, including agents that target vascular endothelial growth factor. To date, the response to these agents has been disappointing, and similar to the response observed in other soft tissue sarcoma subtypes. This short review will summarise the recent data in this field

    Structural analysis of MDM2 RING separates degradation from regulation of p53 transcription activity

    Get PDF
    MDM2–MDMX complexes bind the p53 tumor-suppressor protein, inhibiting p53's transcriptional activity and targeting p53 for proteasomal degradation. Inhibitors that disrupt binding between p53 and MDM2 efficiently activate a p53 response, but their use in the treatment of cancers that retain wild-type p53 may be limited by on-target toxicities due to p53 activation in normal tissue. Guided by a novel crystal structure of the MDM2–MDMX–E2(UbcH5B)–ubiquitin complex, we designed MDM2 mutants that prevent E2–ubiquitin binding without altering the RING-domain structure. These mutants lack MDM2's E3 activity but retain the ability to limit p53′s transcriptional activity and allow cell proliferation. Cells expressing these mutants respond more quickly to cellular stress than cells expressing wild-type MDM2, but basal p53 control is maintained. Targeting the MDM2 E3-ligase activity could therefore widen the therapeutic window of p53 activation in tumors
    corecore